JRCT ID: jRCT2053220084
Registered date:02/09/2022
Exploratory study of IK-01 for knee osteoarthritis
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Osteoarthritis of the knee |
Date of first enrollment | 01/09/2022 |
Target sample size | 10 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | IK-01 is transplanted or IK-01 is transplanted simultaneously with high tibial osteotomy in patients with knee osteoarthritis |
Outcome(s)
Primary Outcome | Change from baseline in the WOMAC total score at 52 weeks post-transplantation |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | < 75age old |
Gender | Both |
Include criteria | - Patients who have provided written informed consent using an IRB-approved explanation/consent form - Patients aged 20 to less than 75 years at the time of informed consent - Patients diagnosed with knee osteoarthritis according to the ACR classification criteria for knee osteoarthritis (clinical findings and X-ray imaging findings) during the screening period - Patients diagnosed with knee osteoarthritis of Kellgren-Lawrence grade 2 or 3 on standing frontal X-ray findings during the screening period |
Exclude criteria | - Patients have multiple arthropathies in the lower extremities - Patients with a history of or need to undergo surgery such as knee meniscectomy or suturing at the time of informed consent. However, if there is a history of meniscal resection or suturing, patients who have passed a certain period (8 weeks or more) after surgery can be enrolled - Patients with a history of or need surgery such as ligament reconstruction for ligament damage of the evaluation target knee at the time of informed consent. However, patients who have passed a certain period (8 weeks or more) after surgery can be enrolled - Patients who are judged to be inappropriate by the principal investigator or sub investigator |
Related Information
Primary Sponsor | Otsuka Koji |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Regenerative medicine Products Development |
Address | 4th Floor, 9-6, Nibancho, Chiyoda Ku, Tokyo 102-0084, Japan Tokyo Japan 102-0084 |
Telephone | +81-3-6457-9861 |
info@hirosaki-li.co.jp | |
Affiliation | Hirosaki Lifescience Innovation, Inc. |
Scientific contact | |
Name | Koji Otsuka |
Address | 4th Floor, 9-6, Nibancho, Chiyoda Ku, Tokyo 102-0084, Japan Tokyo Japan 102-0084 |
Telephone | +81-3-6457-9861 |
info@hirosaki-li.co.jp | |
Affiliation | Hirosaki Lifescience Innovation, Inc. |